Supramolecular PEGylation of Protein Therapeutics

The modification of biomolecules, small molecules, and other agents of via conjugation of excipients, tags, or labels is of great importance. For example, the modification of therapeutic agents can confer improved stability, solubility, duration of action, or pharmacological properties. Supramolecular chemistry utilizes specific, directional, reversible, non-covalent molecular recognition motifs in order to achieve organization of molecules, and can be used to complex tags to agents of interest (e.g., insulin, glucagon, antibodies). The present invention provides useful supramolecular complexes wherein an agent of interest is specifically bound to a host via non-covalent interactions, and wherein the host is conjugated to a tag. The present invention also provides methods and compounds useful in preparing supramolecular complexes, and methods of treating diseases using the supramolecular complexes.

Researchers

Matthew Webber / Eric Appel / Robert Langer / Daniel Anderson

Departments: Office of the Institute Professors, Department of Chemical Engineering
Technology Areas: Biotechnology: Biomanufacturing, Synthetic Biology / Drug Discovery and Research Tools: Genomics & Proteomics / Therapeutics: Proteins & Antibodies, Small Molecules
Impact Areas: Healthy Living

  • supramolecular modification of proteins
    United States of America | Granted | 11,191,841
  • supramolecular modification of proteins
    United States of America | Published application

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.